By contrast, markedly decreased explained variance in chemerin levels in patients with CAD indicated that the effect of RARRES2 polymorphisms was not large enough to alter the risk of mortality and secondary outcomes. This evidence concerns the gene RARRES2 and coronary artery disorder.